Cambridge, Massachusetts-based Editas Medicine (Nasdaq: EDIT) has announced the pricing of an underwritten public offering of common stock and accompanying warrants, structured to raise up to USD 319.4 million in total gross proceeds, as the company advances its in vivo gene editing pipeline — most immediately EDIT-401, an experimental hyperlipidemia program for which new preclinical data were disclosed on the same day as the offering pricing.
The offering comprises 55,555,556 shares of common stock, each accompanied by a common stock warrant to purchase one additional share, priced at a combined USD 2.25 per unit. Pre-funded warrants are available in lieu of common stock for investors who would otherwise exceed beneficial ownership thresholds. Base gross proceeds, assuming no warrant exercise, are expected to reach approximately USD 125 million. Each warrant carries an exercise price of USD 3.50 per share and is exercisable immediately. The warrants expire on the earlier of 30 days following Editas's first public announcement of Phase I clinical data for EDIT-401 showing at least three patients with greater than 80% LDL-cholesterol reduction from baseline with at least one month of follow-up, or three years from issuance. Full exercise of all warrants would generate an additional approximately USD 194.4 million, bringing total potential gross proceeds to approximately USD 319.4 million. The offering was expected to close on or about May 27, 2026, subject to customary closing conditions. Cantor and Wells Fargo Securities are acting as joint book-running managers.
Company overview and pipeline
Editas is a Cambridge, Massachusetts-based gene editing company focused on developing in vivo medicines using CRISPR-based systems. The company holds exclusive licenses to the Broad Institute's Cas12a patent estate and to Broad Institute and Harvard University's Cas9 patent estates for human medicines applications.
The current financing is timed alongside active preclinical advancement of EDIT-401, Editas's in vivo editing candidate targeting hyperlipidemia through LDL-cholesterol reduction.